Fig. 6

Double-targeting of CREB5 and TOP1MT has a potent antitumor effect in cisplatin-resistant HNSCC in vivo. A The tumor weight in nude mice subcutaneously inoculated with HN30/DDP cells treated with cholesterol-modified siCREB5 or/and siTOP1MT (5 μM) at the end of the experiment are shown. B The tumor volume of HN30/DDP cells treated with cholesterol-modified siCREB5 or/and siTOP1M (5 μM) was calculated every 3–4 days, and cisplatin was injected intraperitoneally every 6 days for a total of four times. C Ki67, TOP1MT, and CREB5 in subcutaneous tumor tissue of nude mice were detected and analyzed using IHC. D, E RT-PCR and immunoblotting analysis showed the expression of TOP1MT, CREB5, and GAPDH in the subcutaneous tumor tissue of nude mice. F Sample information of PDX model. G, H Image of mice and tumor after siCREB5 and siTOP1MT administration for 3 weeks. I, J Nude mice were used to construct the PDX model. The treatment group was given siCREB5 and siTOP1MT (5 μM) every day. The tumor volume and weight were recorded every week, and the mice were killed after 3 weeks. *p < 0.05; **p < 0.01; ***p < 0.001 ****p < 0.0001